NCT03250325View on ClinicalTrials.gov

Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients with Synovial Sarcoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

September 20, 2017

Primary Completion Date

January 23, 2020

Study Completion Date

March 9, 2022

Conditions
Synovial Sarcoma
Interventions
BIOLOGICAL

TBI-1301

Split dose of TBI-1301 is administered intravenously for 2 days following cyclophosphamide pre-treatment.

DRUG

Cyclophosphamide

Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1301.

Trial Locations (5)

060-8543

Sapporo Medical University Hospital, Sapporo

514-8507

Mie University Hospital, Tsu

540-0006

National Hospital Organization Osaka National Hospital, Osaka

104-0045

National Cancer Center Hospital, Chuo-ku

812-8582

Kyushu University Hospital, Fukuoka

All Listed Sponsors
lead

Takara Bio Inc.

INDUSTRY

NCT03250325 - Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients with Synovial Sarcoma | Biotech Hunter | Biotech Hunter